[
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-1",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#definitiongeneral488446",
    "clean_content": "Definition / general\n\n* 1 of 2 types of autoimmune pancreatitis* Pancreatic manifestation of IgG4 related disease (IgG4 RD)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-2",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#essentialfeatures488447",
    "clean_content": "Essential features\n\n* Autoimmune pancreatitis is the pancreatic manifestation of IgG4 RD so patients typically have increased IgG4 on serology and other organ involvement by the disease* Diagnosis can be difficult due to rarity, vague presentation and being a mimic of pancreatic ductal adenocarcinoma* International Consensus Diagnostic Criteria (ICDC) for autoimmune pancreatitis has set a standard diagnostic approach and criteria for diagnosis, which includes imaging, serology and histology* Characteristic histologic findings are periductal lymphoplasmacytic infiltrate without granulocytic infiltration, obliterative phlebitis, storiform fibrosis and abundant IgG4 positive plasma cells"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-3",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#terminology488448",
    "clean_content": "Terminology\n\n* Autoimmune pancreatitis (AIP) type 1 or IgG4 related pancreatitis (IgG4 RP)* Historically termed lymphoplasmacytic sclerosing pancreatitis (LPSP) or AIP without granulocyte epithelial lesions (GELs) ([Pancreas 2011;40:352](21412117))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-4",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#icdcoding488449",
    "clean_content": "ICD coding\n\n* ICD-10: [K86.1](https://www.icd10data.com/ICD10CM/Codes/K00-K95/K80-K87/K86-/K86.1) - other chronic pancreatitis* ICD-11: [DC33](https://icd.who.int/browse/2024-01/mms/en#2057951941) - autoimmune pancreatitis"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-5",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#epidemiology488450",
    "clean_content": "Epidemiology\n\n* Patients are generally male and older than 50 years old ([Pathologica 2020;112:197](33179622), [World J Gastroenterol 2022;28:6867](36632320))* Increased prevalence in Asia ([Adv Med Sci 2020;65:403](32805624))* Rare; prevalence is < 1% ([World J Gastroenterol 2022;28:6867](36632320))* Incidence has been increasing due to better description and recognition of the disease but overall numbers are most likely still underestimated due to the complexity of the disease ([World J Gastroenterol 2022;28:6867](36632320))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-6",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#sites488451",
    "clean_content": "Sites\n\n* Pancreatic manifestation of IgG4 RD* Extrapancreatic organ sites can be affected, including salivary and lacrimal glands, retroperitoneum, biliary tree, prostate and kidneys ([Pathologica 2020;112:197](33179622), [World J Gastroenterol 2022;28:6867](36632320), [Adv Med Sci 2020;65:403](32805624))\n    + Other organ involvement is defined as the manifestation of IgG4 related systemic disease and may be diagnosed through imaging, clinical exam or histology ([Pancreas 2011;40:352](21412117))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-7",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#pathophysiology488452",
    "clean_content": "Pathophysiology\n\n* Currently unknown* Still unclear whether the IgG4 antibodies are a reflection of overexpression caused by an unknown inflammatory stimulus or whether they are self reactive autoantibodies* Has been linked to an increase in interferon type I (IFN I) produced by plasmacytoid dendritic cells but this is nonspecific to autoimmune pancreatitis* *H. pylori* infection may be the trigger mechanism for an autoimmune response against pancreatic acini via molecular mimicry but this hypothesis is not supported at this time* Reference: [Adv Med Sci 2020;65:403](32805624)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-8",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#etiology488453",
    "clean_content": "Etiology\n\n* Multifactorial, including genetic, environmental and immunological factors\n  + HLA region genes, *HLA DRB1* and *ABCF1*, are associated with disease susceptibility+ Repeated exposure to certain antigens, including mineral oils, solvents and industrial or metal dusts, may contribute* Reference: [Adv Med Sci 2020;65:403](32805624)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-9",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagrams / tables",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#diagramstables488454",
    "clean_content": "Diagrams / tables\n\nImages hosted on other servers:  \n\n[![AIP diagnostic algorithm](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed01.jpg)](https://journals.lww.com/pancreasjournal/fulltext/2011/04000/international_consensus_diagnostic_criteria_for.3.aspx#O6-3-2)\nâ€ƒ\n[![AIP diagnostic algorithm](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed02.jpg)](https://journals.lww.com/pancreasjournal/fulltext/2011/04000/international_consensus_diagnostic_criteria_for.3.aspx#O6-3-2)\n\nAIP diagnostic algorithm\n\n[![Diagnostic levels](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed_03.png)](https://journals.lww.com/pancreasjournal/_layouts/15/oaks.journals/ImageView.aspx?k=pancreasjournal:2011:04000:00003&i=T1-3&year=2011&issue=04000&article=00003&type=Fulltext)\n\nDiagnostic levels\n\n[![Diagnostic criteria](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed_04.png)](https://journals.lww.com/pancreasjournal/_layouts/15/oaks.journals/ImageView.aspx?k=pancreasjournal:2011:04000:00003&i=T2-3&year=2011&issue=04000&article=00003&type=Fulltext)\n\nDiagnostic criteria"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-10",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#clinicalfeatures488455",
    "clean_content": "Clinical features\n\n* Patients most commonly present with obstructive jaundice ([Pathologica 2020;112:197](33179622), [World J Gastroenterol 2022;28:6867](36632320))* Patients can also present with a pancreatic mass, weight loss or abdominal pain / discomfort but do not present with acute pancreatitis symptoms ([Adv Med Sci 2020;65:403](32805624))* Diabetes commonly occurs with autoimmune pancreatitis ([World J Gastroenterol 2022;28:6867](36632320))* Other manifestations and symptoms of IgG4 RD can be present, including enlargement of the lacrimal and salivary glands as well as retroperitoneal fibrosis and inflammation of the biliary tree ([Adv Med Sci 2020;65:403](32805624))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-11",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#diagnosis488456",
    "clean_content": "Diagnosis\n\n* ICDC for autoimmune pancreatitis was published in 2011, which uses the following combination of categories for diagnosis ([Pancreas 2011;40:352](21412117))\n  + Imaging+ Serology+ Other organ involvement (OOI)+ Histology+ Response to steroid therapy* Can be diagnosed without histology ([Pancreas 2011;40:352](21412117))* Other diagnostic criteria can be used, including the HISORt criteria published by Mayo Clinic; however, the ICDC is the most widely used ([Adv Med Sci 2020;65:403](32805624))* See [Diagrams / tables](https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#pancreasaiptype1diagrams)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-12",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#laboratory488457",
    "clean_content": "Laboratory\n\n* IgG4 > 2 times the upper limit of normal on serology ([Pancreas 2011;40:352](21412117))\n  + Serum IgG4 elevation is the single best marker of autoimmune pancreatitis ([Pancreas 2011;40:352](21412117))+ Elevated IgG4 can also be seen in pancreatic carcinoma patients (10%) and so elevation is not sufficient to make a diagnosis unless seen in the setting of typical imaging or histologic findings ([Adv Med Sci 2020;65:403](32805624), [Pancreas 2011;40:352](21412117))* Positive autoimmune markers are common, including antinuclear antibodies (ANA) (40%), anticarbonic anhydrase II antibodies (55%), antipancreatic secretory trypsin inhibitor (PSTI) antibodies (55%) and antilactoferrin antibodies (75%) ([Adv Med Sci 2020;65:403](32805624))* May have elevated CA 19-9, which can raise suspicion of malignancy ([Pathologica 2020;112:197](33179622))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-13",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#radiologydescription488458",
    "clean_content": "Radiology description\n\n* Parenchymal imaging\n  + Typical: diffuse enlargement with delayed enhancement (sometimes associated with rim-like enhancement)+ Indeterminate (including atypical): segmental / focal enlargement with delayed enhancement* Ductal imaging (endoscopic retrograde cholangiopancreatography [ERCP])\n    + Level 1: long (> one - third length of the main pancreatic duct) or multiple strictures without marked upstream dilatation+ Level 2: segmental / focal narrowing without marked upstream dilatation (duct size < 5 mm)* Diffuse / non-mass forming autoimmune pancreatitis\n      + Diffuse pancreas enlargement (\"sausage\" pancreas), often with low density edge (halo ring sign or capsule sign) on computed tomography (CT) ([World J Clin Cases 2022;10:12458](36483806))+ Contrast can highlight the capsule and shows mild enhancement during the venous or delayed phase ([World J Clin Cases 2022;10:12458](36483806))* Mass forming autoimmune pancreatitis\n        + Often shows a low density or isodense mass in the head of the pancreas on CT ([World J Clin Cases 2022;10:12458](36483806))+ Contrast enhanced CT shows slight enhancement of the lesion in the arterial phase and obvious uniformity and delayed enhancement in the venous phase ([World J Clin Cases 2022;10:12458](36483806))* Ducts\n          + Smooth stenosis at the lower end of the common bile duct can be shown in autoimmune pancreatitis patients with obstructive jaundice ([World J Clin Cases 2022;10:12458](36483806))+ Pancreatic duct is usually irregularly narrow and interrupted and often exceeds one - third of the total length of the main pancreatic duct or appears as a jumping stenosis ([World J Clin Cases 2022;10:12458](36483806))* Contrast enhanced CT and magnetic resonance imaging (MRI) show similar results; ultrasound can be variable in diagnostic quality ([Adv Med Sci 2020;65:403](32805624))* Other organ involvement can also be seen on imaging and help support the diagnosis of autoimmune pancreatitis"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-14",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#radiologyimages488459",
    "clean_content": "Radiology images\n\nImages hosted on other servers:  \n\n[![CT](https://www.pathologyoutlines.com/thumb/pancreasaiptype1radio1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562966/figure/F2/)\n\nCT\n\n[![PET](https://www.pathologyoutlines.com/thumb/pancreasaiptype1radio2.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562966/figure/F1/)\n\nPET\n\n[![Endoscopic ultrasound](https://www.pathologyoutlines.com/thumb/pancreasaiptype1radio3.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562966/figure/F3/)\n\nEndoscopic ultrasound\n\n[![ERCP with stricture](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed05.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876015/figure/F2/)\n\nERCP with stricture\n\n  \n\n[![Ultrasound](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed06.jpg)](https://radiopaedia.org/cases/88443/studies/105100?lang=us#findings)\n\nUltrasound\n\n[![MRI](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed07.jpg)](https://radiopaedia.org/cases/88443/studies/105101?lang=us#findings)\n\nMRI\n\n[![Mass forming autoimmune pancreatitis (CT)](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed08.jpg)](https://radiopaedia.org/cases/21642/studies/21596?lang=us#findings)\n\nMass forming autoimmune pancreatitis (CT)\n\n[![Mass forming autoimmune pancreatitis (PET)](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed09.jpg)](https://radiopaedia.org/cases/21642/studies/21597?lang=us#findings)\n\nMass forming autoimmune pancreatitis (PET)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-15",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#prognosticfactors488460",
    "clean_content": "Prognostic factors\n\n* Patients commonly relapse (40%) despite remarkable responses to treatment ([Pathologica 2020;112:197](33179622), [Adv Med Sci 2020;65:403](32805624))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-16",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#casereports488461",
    "clean_content": "Case reports\n\n* 49 year old woman with weight loss, abdominal pain and jaundice ([Cureus 2023;15:e47471](38022068))* 54 year old man with weight loss and abdominal pain status post-COVID vaccine ([ACG Case Rep J 2023;10:e00950](36713283))* 55 year old man with weight loss, jaundice and pruritus ([Cureus 2023;15:e45970](37900366))* 64 year old Japanese woman with new onset bleeding due to acquired hemophilia A with known longstanding disease ([Int J Hematol 2018;108:335](29582334))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-17",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#treatment488462",
    "clean_content": "Treatment\n\n* Steroids are the main treatment strategy\n  + Steroid trial of prednisone 0.6 - 1 mg/kg for 2 weeks with improvement on repeat imaging and serology can be confirmatory in the appropriate context ([Pancreas 2011;40:352](21412117))+ Steroid trial should not be done in isolation for diagnosis of autoimmune pancreatitis ([Pancreas 2011;40:352](21412117))* Immunosuppressants or rituximab can be started if corticosteroids are not effective or cannot be tolerated* Patients with asymptomatic disease should be treated to prevent the progression of fibrotic changes and decrease the risk of developing pancreatic insufficiency or relapse* Follow up should consist of a combination of methods (symptoms, serology, imaging) and not IgG4 levels alone* Endoscopic procedures may be needed in cases of insufficient drug effect or obstructive jaundice* Surgery should be reserved for cases where malignancy cannot be excluded, extensive fibrosis is present or endoscopic biliary drainage cannot be performed* Reference: [Adv Med Sci 2020;65:403](32805624)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-18",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#grossdescription488463",
    "clean_content": "Gross description\n\n* Disease is localized mainly in the pancreatic head, less frequently in the body / tail* Diffuse enlargement or \"sausage\" pancreas may be observed without a discrete mass* Segmental stenosis of the main duct may be seen* References: [Pathologica 2020;112:197](33179622), [Abdom Radiol (NY) 2016;41:1003](27193798), [World J Gastroenterol 2022;28:6867](36632320)"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-19",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#grossimages488464",
    "clean_content": "Gross images\n\nContributed by Aaron R. Huber, D.O.  \n\n[![Ill defined fibrosis](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber01.jpg)\n\nIll defined fibrosis\n\n  \n  \nImages hosted on other servers:  \n\n[![Nodular lesions](https://www.pathologyoutlines.com/thumb/pancreasaiptype1gross1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731143/figure/F2/)\n\nNodular lesions\n\n[![Ill defined pancreatic head mass](https://www.pathologyoutlines.com/thumb/pancreasAIPtype1pubmed10.jpg)](https://radiopaedia.org/cases/21642/studies/21598?lang=us#findings)\n\nIll defined pancreatic head mass"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-20",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#microscopichistologicdescription488465",
    "clean_content": "Microscopic (histologic) description\n\n* Characteristic findings (at least 3 for level 1 criteria) ([Pancreas 2011;40:352](21412117))\n  + Periductal lymphoplasmacytic infiltrate without granulocytic infiltration+ Obliterative phlebitis+ Storiform fibrosis+ Abundant (> 10 cells/high power field) IgG4 positive plasma cells* Biopsy showing some but not all of the above features can be used as supportive evidence for the diagnosis of autoimmune pancreatitis ([Pancreas 2011;40:352](21412117))* Inflammation is localized within the pancreatic parenchyma and is centered around / within medium to large interlobular ducts, which causes shrinkage of the ductal lumen ([Pathologica 2020;112:197](33179622))* Inflammation can also be seen between the pancreatic parenchyma and peripancreatic adipose tissue ([Pathologica 2020;112:197](33179622))* Inflammation of the venous wall can progress to obliterative phlebitis with fibrosis of the lumen ([Pathologica 2020;112:197](33179622))* As the inflammation progresses, fibrosis becomes more diffuse, assuming a whorled or storiform pattern ([Pathologica 2020;112:197](33179622))* Perineural inflammation can also be present ([Pathologica 2020;112:197](33179622))* Involvement of the pancreatic neck margin or biliary resection margin should be clearly stated in the pathology report for therapeutic purposes ([Pathologica 2020;112:197](33179622))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-21",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#microscopichistologicimages488466",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Aaron R. Huber, D.O. and [@RaulSGonzalezMD](https://twitter.com/RaulSGonzalezMD) on Twitter  \n\n[![Fibrosis and inflammation](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber02.jpg)\nâ€ƒ\n[![Fibrosis and inflammation](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber03.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber03.jpg)\nâ€ƒ\n[![Fibrosis and inflammation](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber06.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber06.jpg)\n\nFibrosis and inflammation\n\n[![Inflammation](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber04.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber04.jpg)\n\nInflammation\n\n[![Fibrosis](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber05.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber05.jpg)\n\nFibrosis\n\n[![Phlebitis](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber07.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber07.jpg)\n\nPhlebitis\n\n  \n\n[![Phlebitis](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber08.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber08.jpg)\n\nPhlebitis\n\n[![Autoimmune pancreatitis type 1](https://www.pathologyoutlines.com/imgau/pancreasaiptype1RaulSGonzalezMD01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasaiptype1RaulSGonzalezMD01.jpg)\nâ€ƒ\n[![Autoimmune pancreatitis type 1](https://www.pathologyoutlines.com/imgau/pancreasaiptype1RaulSGonzalezMD02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasaiptype1RaulSGonzalezMD02.jpg)\n\nAutoimmune pancreatitis type 1\n\n[![Elastic stain](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber09.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber09.jpg)\n\nElastic stain\n\n[![IgG4](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber10.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber10.jpg)\nâ€ƒ\n[![IgG4](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber11.jpg)](https://www.pathologyoutlines.com/imgau/pancreasAIPtype1huber11.jpg)\n\nIgG4"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-22",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#cytologydescription488467",
    "clean_content": "Cytology description\n\n* FNA has variable results with diagnosing autoimmune pancreatitis type 1 but can be used to rule out malignancy in mass forming lesions ([Diagnostics (Basel) 2021;11:1653](34573995))* Lymphoplasmacytic infiltration, storiform fibrosis and obliterative phlebitis can be seen alone or in combination ([Diagnostics (Basel) 2021;11:1653](34573995), [World J Gastroenterol 2012;18:3883](22876041))"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-23",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#cytologyimages488468",
    "clean_content": "Cytology images\n\nImages hosted on other servers:  \n\n[![Type 1](https://www.pathologyoutlines.com/thumb/pancreasaiptype1cyto1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413061/figure/F2/)\n\nType 1 FNA"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-24",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#positivestains488469",
    "clean_content": "Positive stains\n\n* [IgG](https://www.pathologyoutlines.com/topic/stainsIgA.html) and [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html)\n  + > 10 [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html) positive cells per high power field in biopsy specimens ([Pancreas 2011;40:352](21412117))+ > 50 [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html) positive cells per high power field in resection specimens ([Virchows Arch 2018;472:545](29196804))+ [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html)/[IgG](https://www.pathologyoutlines.com/topic/stainsIgA.html) ratio > 40% ([Virchows Arch 2018;472:545](29196804))* [Elastic](https://www.pathologyoutlines.com/topic/stainselastic.html): highlights remnant veins in longstanding autoimmune pancreatitis* [Masson trichrome](https://www.pathologyoutlines.com/topic/stainstrichrome.html): highlights storiform fibrosis* Normal / intact expression of [DPC4](https://www.pathologyoutlines.com/topic/stainsdpc4.html) in entrapped ducts"
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-25",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#samplepathologyreport488470",
    "clean_content": "Sample pathology report\n\n* Pancreas, mass, core needle biopsy:\n  + Chronic pancreatitis with storiform fibrosis and increased IgG4 positive plasma cells (see comment)+ Negative for malignancy+ Comment: H&E sections demonstrate pancreatic parenchyma with dense storiform fibrosis and numerous chronic inflammatory cells including abundant plasma cells. A partially obliterated vein is seen. Immunohistochemical stain for IgG4 shows increased IgG4 positive plasma cells (up to 20 - 25 per high power field). The combined findings are most consistent with autoimmune pancreatitis type 1."
  },
  {
    "id": "autoimmune-pancreatitis-type-1_46654_1750166972.txt-26",
    "source_document": "autoimmune-pancreatitis-type-1_46654_1750166972.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasaiptype1.html#differentialdiagnosis488471",
    "clean_content": "Differential diagnosis\n\n* [Pancreatic ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html):\n  + Can have similar presentation (vague abdominal symptoms, jaundice, pancreatic mass) with similar radiographic findings and serology (increased [CA 19-9](https://www.pathologyoutlines.com/topic/stainsca19-9.html) with or without increased [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html))+ Infiltrating well to poorly formed glandular / ductal structures surrounded by remarkably desmoplastic stroma+ Perineural or lymphovascular invasion+ Molecular alterations not present in AIP type 1 ([World J Gastroenterol 2023;29:2241](37124888))* [Autoimmune pancreatitis type 2](https://www.pathologyoutlines.com/topic/pancreasaiptype2.html):\n    + Younger patients with no sex predilection+ Associated with chronic inflammatory bowel disease+ Serum [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html) antibody levels are within normal ranges+ Requires histological specimen to make definitive diagnosis ([Pancreas 2011;40:352](21412117))+ Duct centric granulocytic abscesses and lobular (but not storiform) fibrosis* **Follicular pancreatitis**:\n      + Inflammation with numerous lymphoid follicles with or without prominent germinal centers+ Lacks storiform fibrosis, obliterative phlebitis and [IgG4](https://www.pathologyoutlines.com/topic/stainsigg4.html)+ cells* [Obstructive chronic pancreatitis](https://www.pathologyoutlines.com/topic/pancreaschronic.html):\n        + Groups of acini and tubules scattered in fibrous tissue"
  }
]